Omega Diagnostics (CNSL) AI Stock Analysis

• Market Cap: £5.47M
• Dividend Yield: N/A
• Average Volume (3M): 353.57K
• Price to Earnings (P/E): 4.0
• Beta (1Y): 1.32
• Revenue Growth: -10.20%
• EPS Growth: 714.29%
• Country: UK
• Employees: 94
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 0.00
• Shares Outstanding: 237,950,650
• 10 Day Avg. Volume: 111,535
• 30 Day Avg. Volume: 353,573
• PEG Ratio: >-0.01
• Price to Book (P/B): 0.64
• Price to Sales (P/S): 0.87
• P/FCF Ratio: -51.18
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 50 Neutral
• Price Target: 2.50p ▲(8.70% Upside)

The overall stock score is primarily influenced by the mixed financial performance and bearish technical indicators. While the valuation suggests the stock may be undervalued, significant financial and technical challenges weigh heavily on the score. The positive sentiment from leadership's share acquisitions provides a minor offset but is not enough to significantly alter the overall outlook.

Positive Factors

Low leverage / strong balance sheet

Extremely low leverage and a double-digit ROE provide durable financial stability, giving the company flexibility to absorb shocks, fund targeted investments, and pursue strategic opportunities without immediate refinancing pressures, supporting medium-term resilience.

High gross and net margins

Sustained high gross and positive net margins indicate a profitable product mix and pricing power in in vitro diagnostics. These structural margins can support R&D, product quality, and selective commercial investment, underpinning long-term competitive positioning.

Management alignment via share purchases

Senior management buying shares signals alignment with shareholders and confidence in execution. This alignment tends to improve governance, incentivize long-term value creation, and reduce agency risk, supporting steadier strategic decision-making over months ahead.

Negative Factors

Declining revenue trend

Consistent revenue contraction erodes scale benefits and market share, increasing per-unit costs and stressing commercial channels. Over 2–6 months this trend can force tougher pricing, reduce investment capacity, and weaken negotiating power with customers and suppliers.

Severe cash flow deterioration

Material negative free cash flow growth and poor cash conversion signal liquidity strain and weakened internal funding. Even with low debt, persistent cash shortfalls limit reinvestment, raise refinancing risk for capex or working capital, and constrain strategic flexibility long-term.

Operational inefficiencies (negative EBIT)

Negative EBIT alongside strong gross margins indicates rising operating costs or poor cost control. Structural operating inefficiency reduces ability to convert sales into sustainable profits, pressuring margins and requiring corrective actions to restore competitive economics.

Omega Diagnostics Business Overview & Revenue Model

Company Description

Cambridge Nutritional Sciences plc, through its subsidiaries, develops, manufactures, and distributes medical diagnostics products for the food sensitivity testing market. The company is involved in the research, development, and production of kits for detection of immune reactions to food under the Foodprint name. It provides clinical analysis to the general public, clinics, and health professionals, as well as supplies Food Detective, a consumer food test. The company serves government, private hospitals, reference laboratories, nutritionists, naturopaths, and other healthcare professionals. Cambridge Nutritional Sciences plc operates in the United Kingdom, rest of Europe, North America, South/Central America, India, other Asian countries and the Far East, Africa, and the Middle East. The company was formerly known as Omega Diagnostics Group PLC and changed its name to Cambridge Nutritional Sciences plc in September 2023. Cambridge Nutritional Sciences plc was founded in 1987 and is based in London, the United Kingdom.

How the Company Makes Money

Omega Diagnostics generates revenue through the sale of its diagnostic products, which are marketed to hospitals, laboratories, and healthcare providers. The company has established key revenue streams from the distribution of its allergy testing kits and infectious disease diagnostics, which are often sold directly to healthcare facilities or through third-party distributors. Additionally, Omega may benefit from partnerships with other companies in the healthcare and diagnostics sectors, which can provide access to new markets and enhance its product offerings. The ongoing demand for accurate diagnostic testing in the healthcare industry, particularly in light of emerging health challenges, plays a significant role in sustaining and growing its earnings.

Omega Diagnostics Financial Statement Overview

Summary

Omega Diagnostics presents a mixed financial picture. The income statement shows profitability but declining revenue and operational inefficiencies. The balance sheet is strong with low leverage and reasonable returns on equity, indicating financial stability. However, the cash flow statement highlights significant cash management challenges and potential liquidity risks.

Income Statement

Omega Diagnostics shows a mixed performance in its income statement. The company has a positive net profit margin of 18.80% in the latest year, indicating profitability. However, the revenue growth rate is negative at -7.18%, suggesting a decline in sales. The gross profit margin is healthy at 60.08%, but the EBIT margin is negative, reflecting operational challenges. Overall, the income statement reflects profitability but with declining revenue and operational inefficiencies.

Balance Sheet

The balance sheet of Omega Diagnostics is relatively strong with a low debt-to-equity ratio of 0.03, indicating low leverage and financial stability. The return on equity is 13.73%, showing a decent return for shareholders. The equity ratio is not explicitly calculated, but the low debt levels suggest a strong equity position. Overall, the balance sheet reflects financial stability with low leverage and reasonable returns on equity.

Cash Flow

Cash flow analysis reveals significant challenges for Omega Diagnostics. The free cash flow growth rate is negative at -125.27%, indicating deteriorating cash generation. The operating cash flow to net income ratio is low at 0.04, suggesting weak cash conversion. The free cash flow to net income ratio is negative, highlighting cash flow issues. Overall, the cash flow statement indicates significant cash management challenges and potential liquidity risks.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	8.06M	8.33M	9.77M	7.55M	8.54M	6.82M
Gross Profit	4.91M	5.00M	6.05M	3.17M	4.75M	4.00M
EBITDA	2.01M	2.20M	-73.00K	-2.65M	-382.00K	418.00K
Net Income	1.36M	1.57M	-328.00K	-3.86M	-11.33M	-2.10M
Balance Sheet
Total Assets	12.69M	13.80M	13.89M	14.40M	17.84M	29.55M
Cash, Cash Equivalents and Short-Term Investments	3.59M	4.87M	5.44M	5.12M	1.60M	5.83M
Total Debt	237.00K	349.00K	148.00K	74.00K	370.00K	2.84M
Total Liabilities	1.64M	2.39M	4.21M	4.45M	6.02M	6.16M
Stockholders Equity	11.05M	11.41M	9.68M	9.95M	11.82M	23.38M
Cash Flow
Free Cash Flow	-437.00K	-142.00K	548.00K	-3.31M	-4.71M	-5.24M
Operating Cash Flow	-166.00K	83.00K	607.00K	-3.15M	-3.23M	-2.42M
Investing Cash Flow	-482.00K	2.12M	-2.51M	5.18M	-493.00K	-2.83M
Financing Cash Flow	-233.00K	-251.00K	-265.00K	1.49M	-502.00K	11.07M

Omega Diagnostics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.30
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:CNSL, the sentiment is Positive. The current price of 2.3 is above the 20-day moving average (MA) of 2.02, above the 50-day MA of 2.21, and below the 200-day MA of 2.91, indicating a neutral trend. The MACD of 0.01 indicates Negative momentum. The RSI at 76.14 is Negative, neither overbought nor oversold. The STOCH value of 71.77 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:CNSL.

Omega Diagnostics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TSTL	77 Outperform	£203.00M	30.53	20.31%	3.48%	10.80%	1.75%
AMS	69 Neutral	£478.01M	52.00	3.66%	1.25%	68.03%	-18.27%
EKF	67 Neutral	£114.80M	19.63	8.71%	―	-1.43%	28.57%
IXI	58 Neutral	£10.89M	-6.32	-15.57%	―	13.32%	55.07%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CNSL	50 Neutral	£5.47M	4.04	13.26%	―	-10.20%	714.29%
ABDX	45 Neutral	£15.69M	-6.58	-90.48%	―	37.39%	-126.19%

Omega Diagnostics Corporate Events

Cambridge Nutritional Sciences Leadership Increases Shareholdings

Cambridge Nutritional Sciences plc announced that Carolyn Rand, Non-Executive Chair, and Jeremy Millard, Non-Executive Director, have acquired additional shares in the company. Rand purchased 150,000 shares at an average price of 2.32 pence, while Millard acquired 168,776 shares at 2.37 pence each. These transactions reflect a vote of confidence in the company’s future prospects by its leadership, potentially impacting stakeholder perceptions and market positioning.

The most recent analyst rating on (GB:CNSL) stock is a Hold with a £3.00 price target. To see the full list of analyst forecasts on Omega Diagnostics stock, see the GB:CNSL Stock Forecast page.

Cambridge Nutritional Sciences Reports Revenue Decline but Improves Gross Margin

Cambridge Nutritional Sciences reported a decrease in revenue for the first half of 2025, with sales dropping to £3.9 million from £4.1 million in the same period last year. Despite this, the company achieved an improved gross margin of 67.7% due to production efficiencies and a favorable product mix. The company has restructured its sales and marketing teams to focus on long-term growth, particularly in regions where sales have lagged, such as mainland Europe. While the company expects full-year sales to be lower than the previous year, it remains confident in its strategic objectives, supported by a strong cash position and ongoing investments in new initiatives.

The most recent analyst rating on (GB:CNSL) stock is a Hold with a £3.00 price target. To see the full list of analyst forecasts on Omega Diagnostics stock, see the GB:CNSL Stock Forecast page.

Cambridge Nutritional Sciences to Announce Half Year Results and Host Investor Presentation

Cambridge Nutritional Sciences plc has announced it will release its Half Year results for the six months ended 30 September 2025 on 10 November 2025. The company will host a live online presentation for shareholders and potential investors on the same day to discuss the results, providing an opportunity for engagement and transparency with stakeholders.

The most recent analyst rating on (GB:CNSL) stock is a Hold with a £3.00 price target. To see the full list of analyst forecasts on Omega Diagnostics stock, see the GB:CNSL Stock Forecast page.